WP 9 – ‘Response to therapies’ will incorporate different registries and clinical trial populations and develop new clinical trial criteria to find and recruit suitable patients in order to increase the relevance of clinical trial outcomes and, thus, the success of such trials. The work package will further try to establish a personalised medicine approach to RA therapy through characterization and the development of peripheral blood biomarkers. Importantly, it will also investigate the reaction on interventional treatment against RA in in subjects who are at significant risk of developing RA.
Academic WP-leader: Danielle Gerlag, Dominique Baeten
EFPIA WP-leader: Dick de Vries